Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes-Reference-Cited by-同舟云学术

Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

Published:2018-11-26 Issue:5 Volume:120 Page:8534-8546
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J Cell Biochem

Author:

Kim Ji‐Won¹,Lee Ye‐Jee¹,You Young‐Hye¹,Moon Min Kyong²,Yoon Kun‐Ho¹,Ahn Yu‐Bae³,Ko Seung‐Hyun³^ORCID

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea Seoul Korea

2. Division of Endocrinology and Metabolism, Department of Internal Medicine Seoul National University Boramae Medical Center, Seoul University College of Medicine Seoul Korea

3. Division of Endocrinology and Metabolism, Department of Internal Medicine St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea Seoul Korea

Funder

Basic Science Research Program through the National Research Foundation of Korea

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcb.28141

Reference49 articles.

1. Nonalcoholic Fatty Liver Disease

2. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

3. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association